Isolated Systolic Hypertension (ISH): Treatment

Definition & Pathophysiology

Lifestyle Modifications (First Step for All)

• Sodium restriction (< 2.3 g/day)
• Weight reduction if overweight
• DASH diet
• Regular aerobic exercise
• Smoking cessation
• Moderation of alcohol intake

Pharmacological Treatment

First-Line Agents

• Thiazide diuretics are often preferred as first-line: the landmark SHEP trial demonstrated that low-dose chlorthalidone (± atenolol or reserpine as step-up) significantly reduced stroke and CV events in elderly ISH patients.
• Long-acting CCBs (e.g., amlodipine) are effective in lowering BP and reducing cardiovascular events in elderly patients with ISH and may be a preferred option in this group — Goodman & Gilman's Pharmacological Basis of Therapeutics.
• ACE inhibitors are recommended for the elderly without particular comorbidities as second-line agents, and are first-line when CKD or diabetes coexists (Swanson's Family Medicine Review).

Combination Therapy

• Thiazide + ACE inhibitor/ARB
• Thiazide + CCB
• ACE inhibitor + CCB (e.g., perindopril + amlodipine — shown superior to atenolol + HCTZ in ASCOT-BPLA)

Blood Pressure Targets in ISH

• General target: SBP < 140 mmHg
• Elderly (≥ 80 years): SBP 140–150 mmHg is acceptable per earlier guidelines; more intensive targets (< 130 mmHg) may provide additional benefit if well tolerated (SPRINT data)
• Critical caveat — J-curve: Excessive DBP lowering must be avoided. The relationship between DBP and CV mortality follows a J-curve. JNC 7 recommends a minimum post-treatment DBP of 60 mmHg (or 65 mmHg in known CAD), as too-low diastolic pressures compromise coronary perfusion — Brenner & Rector's The Kidney.
• Both JATOS and VALISH trials found no additional benefit of targeting SBP < 140 mmHg vs. < 150 mmHg in elderly Japanese patients with ISH.

Special Populations

Agents to Avoid / Use Cautiously

• Short-acting dihydropyridines (immediate-release nifedipine): no role in hypertension management
• High-dose thiazides: risk of hypokalemia, hyperuricemia, glucose intolerance
• Beta-blockers: not preferred as first-line in isolated ISH without compelling indication (may mask hypoglycemia in insulin-dependent DM; peripheral vasoconstriction worsens PVD)
• Reserpine: historically used (SHEP trial as alternative), but no longer recommended due to CNS side effects (depression risk) given availability of superior agents

Key Evidence Base

Summary Algorithm

1. Lifestyle modification for all
2. SBP 140–159 mmHg: Start monotherapy — thiazide diuretic or long-acting CCB (reduce doses in elderly)
3. SBP ≥ 160 mmHg: Consider dual therapy from the outset
4. Comorbidities guide choice of additional agents (ACE inhibitor/ARB for CKD/DM; beta-blocker for CAD)
5. Monitor DBP: avoid dropping below 60 mmHg (65 mmHg if CAD present)
6. Target: SBP < 140 mmHg; consider < 130 mmHg if young/tolerated; SBP 140–150 mmHg acceptable in frail elderly ≥ 80 years

Sources: Swanson's Family Medicine Review; Goodman & Gilman's Pharmacological Basis of Therapeutics; Brenner & Rector's The Kidney; Comprehensive Clinical Nephrology, 7e; Brunström et al. Blood Press 2023 [PMID 37395100]; Thomopoulos J Hypertens 2023 [PMID 37909131]

ISH Treatment: Elderly Female + Diabetes + Post-Radical Gastrectomy for Stage III Gastric Cancer

1. Isolated systolic hypertension (age-related arterial stiffness)
2. Diabetes mellitus (changes drug preference and BP target)
3. Post-radical gastrectomy with lymphadenectomy (hemodynamic instability, drug absorption changes, dumping syndrome, vagal disruption, nutritional consequences)
4. Stage III gastric carcinoma (cancer survival consideration, future chemotherapy interactions)

Step 1: Pre-Treatment Assessment

• Baseline orthostatic BP (sitting vs. standing) — post-gastrectomy autonomic disruption and nutritional depletion increase orthostatic hypotension risk
• Postprandial BP — dumping syndrome causes dramatic post-meal hypotension; record BP before and 30–60 min after meals
• Nutritional and volume status — significant protein-calorie malnutrition is present in >80% of post-surgical gastric cancer patients; hypovolemia may falsely elevate or mask true BP
• Renal function / eGFR + urinary albumin — determines if ACE inhibitor/ARB is indicated for diabetic nephroprotection
• Electrolytes — potassium, magnesium (relevant before starting diuretics)
• HbA1c and glycemic control — guides antidiabetic co-management alongside antihypertensive choice
• Current medications — including any planned adjuvant chemotherapy (many regimens, e.g., CAPOX, interact with antihypertensives)

Step 2: Drug of Choice — ACE Inhibitor or ARB

• Diabetes with hypertension mandates RAS blockade as the compelling indication — renoprotection (reduces progression to diabetic nephropathy), reduces microalbuminuria, and slows CKD progression (Goldman-Cecil Medicine; Swanson's Family Medicine; Brenner & Rector's The Kidney)
• ACE inhibitors are effective across all severity levels of hypertension in diabetic patients regardless of age or sex (Brenner & Rector's)
• Oncological consideration: In post-gastrectomy gastric cancer, a prospective cohort of 3,012 patients (FIESTA study, Wang et al., BMC Gastroenterology 2022) found that antihypertensive therapy was associated with a 42% reduction in mortality risk (HR 0.58) in post-surgical gastric cancer patients. ACE inhibitors/ARBs have pleiotropic anti-tumor and anti-inflammatory properties relevant to stage III disease [PMID: 36210441]

• Prefer ARB if the patient develops ACE inhibitor cough (common in elderly women) or has a history of angioedema
• Avoid dual RAS blockade (ACE inhibitor + ARB combined) — increased risk of hyperkalemia and acute kidney injury without added benefit

Step 3: Add Long-Acting CCB if Target Not Achieved

• Highly effective in elderly ISH with low-renin physiology (Goodman & Gilman's)
• Calcium channel blockers demonstrated improved prognosis in post-gastrectomy gastric cancer patients — the FIESTA study found CCBs superior to other antihypertensive classes for survival benefit [PMID: 36210441]
• ACE inhibitor + CCB combination is supported by ASCOT-BPLA (perindopril + amlodipine superior to atenolol + HCTZ)
• Avoid non-dihydropyridines (verapamil, diltiazem) in elderly — excessive negative chronotropy, constipation (problematic post-gastrectomy), and high drug interaction potential

Step 4: Use Thiazide Diuretics with Caution

Step 5: Avoid Beta-Blockers as First-Line

• No compelling indication here (no CAD, no heart failure, no post-MI status)
• Mask hypoglycemic symptoms in a diabetic patient on insulin or sulfonylurea
• Reduce peripheral circulation, worsening malnutrition-related perfusion issues
• May worsen post-gastrectomy fatigue and functional decline

Critical Post-Gastrectomy BP Considerations

Dumping Syndrome and BP

• Fluid shift into hyperosmolar duodenal lumen
• Release of vasodilatory GI hormones (VIP, neurotensin, peptide YY, enteroglucagon)

Vagal Disruption

• Impairs baroreceptor reflex
• Predisposes to orthostatic hypotension
• Alters drug absorption kinetics (changes gastric emptying rate)

Drug Absorption Post-Gastrectomy

• Altered gastric pH → changes tablet dissolution
• Reduced gastric reservoir volume → altered drug mixing
• Faster small intestinal transit → shorter absorption window
• Prefer immediate-release formulations over extended-release preparations when possible, as slow-release tablets may pass through incompletely absorbed
• Amlodipine (intrinsically long half-life, not a modified-release formulation) is pharmacokinetically favorable in this setting
• Ramipril/perindopril (immediate-release capsules) are acceptable; valsartan/losartan are also fine
• Avoid extended-release formulations (e.g., metoprolol succinate XR, nifedipine GITS) — dissolution may be impaired

BP Targets

Monitoring Plan

Adjuvant Chemotherapy Interactions

• Capecitabine can cause vasoconstriction and hand-foot syndrome; CCBs do not interact adversely
• Ramucirumab (if used for advanced/recurrent disease) causes hypertension as a class effect (anti-VEGF) — would require upward titration of antihypertensives; CCBs and ACE inhibitors are preferred in this setting
• Monitor BP closely during any chemotherapy cycle

Summary Recommendation

*Sources: Goldman-Cecil Medicine; Goodman & Gilman's Pharmacological Basis of Therapeutics; Brenner & Rector's The Kidney; Sleisenger & Fordtran's GI and Liver Disease; Maudsley Prescribing Guidelines 15e; Wang et al. BMC Gastroenterol 2022 [PMID 36210441]*The key points that make this case distinct from standard ISH management:

1. Dumping-related postprandial hypotension — antihypertensives potentiate the vasodilatory GI hormone surge that causes early dumping; BP measurements must be pre-prandial
2. Vagotomy-related baroreceptor impairment — autonomic blunting increases orthostatic hypotension risk; check standing BP at every visit
3. Drug absorption alteration — gastric reservoir loss changes dissolution and transit; avoid extended-release formulations, favor immediate-release preparations (ramipril capsules, standard amlodipine tablets)